Navigation Links
Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
Date:8/19/2008

DURHAM, N.C., Aug. 19 /PRNewswire/ -- Addrenex Pharmaceuticals ( http://www.addrenex.com ) has made three strategic hires this month to further its goal of identifying and developing as many new drug candidates as possible over the next 18 months.

The fast-paced timeline they have set for drug discovery mirrors the company's recent successes in developing two new drugs, Clonicel(R) for attention deficit/hyperactivity disorder and CloniBID for hypertension, over the past two years. A new drug application has already been filed for CloniBID, with Food and Drug Administration review expected by December 2008, and Clonicel is in phase 3 clinical trials. Commercial rights to both drugs have been granted to Atlanta-based Sciele Pharma.

The additions of Steven Butts, M.B.A., as vice president of commercial operations and Gary Bream, Ph.D., as senior director of scientific affairs will strengthen Addrenex's ability to pursue additional drugs to treat conditions such as menopausal flushing, pain, addiction, aggression, and post traumatic stress disorder, said Moise Khayrallah, Ph.D., cofounder and chief executive officer of Addrenex. Yuki Prescott has also joined as clinical trials manager and will enhance the clinical team's ability to oversee a growing clinical program.

"We now have a solid partnership in place with Sciele that will enable us to develop our lead compounds and to pursue additional compounds in our portfolio that target the alpha-2 adrenergic receptors," said Khayrallah. "We're using our lead compounds to power the rest of the portfolio. The highly skilled team we have now assembled gives us the capability to deliver on our commitments and meet our fast-paced timelines."

The indications being targeted by Addrenex are each associated with an overactive adrenergic system, a group of hormones produced by the adrenal glands that regulate the body's reaction to stress, hormonal
'/>"/>

SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
2. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
5. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
6. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
9. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
11. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Inhibikase Therapeutics, Inc., an emerging ... it will present new results on its antiviral ... sponsored by the PML Consortium (composed of Pfizer, ... (JCV) is the causative agent of Progressive Multifocal ... in an extended release formulation, can clear JC ...
(Date:5/23/2013)... 23, 2013 InspireMD, Inc. ... leader in embolic protection stents, today announced new ... ST Elevation Reperfusion) trial demonstrating that the MGuard ... drug eluting stents in all-cause mortality in ST ... the trial were presented at the InspireMD STEMI ...
(Date:5/23/2013)... and PARIS , May 23, ... a leading developer and manufacturer of precision guided therapy ... coronary and peripheral vascular disease, today announced preliminary results ... I ndependent S tenosis E valuation) ... trial session at EuroPCR 2013. These prospective results confirm ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5
... BAY, Wis., Sept. 7, 2011 ... solutions to hospitals, IDNs, healthcare systems and clinics, ... of the Centers for Medicare & Medicaid Services ... Medical Documentation (esMD).  (Logo: http://photos.prnewswire.com/prnh/20110907/PH63482LOGO) ...
... 7, 2011 As NFL coaches and players face a ... one team,s preparation will be gaining a competitive edge as ... season. Today, Polar USA and the Atlanta Falcons announced that ... "Official Heart Rate Training System" of the Atlanta Falcons. ...
Cached Medicine Technology:IOD to Enter Testing Phase in CMS esMD Pilot Program 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 3
(Date:5/23/2013)... a study in 2012 suggested a cancer drug ... with Alzheimer,s disease, three groups of researchers now ... findings. The teams said their research could ... drug involved in the study, bexarotene (Targretin), has ... pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, ...
(Date:5/23/2013)... Emory Vaccine Center have shown that an immune regulatory ... in mice against viral infections. , The results are ... "Our findings highlight how IL-21 could be important in ... Ur Rasheed Mohammed, PhD, the first author of the ... of the Emory Vaccine Center and a Georgia Research ...
(Date:5/23/2013)... Chicago, IL (PRWEB) May 23, 2013 ... of comprehensive solutions and educational resources for the ... today that it is opening its first global ... in the Philippines in August. This new world-class ... the best of Western evidence-based practices to treat ...
(Date:5/23/2013)... 23, 2013 Six innovative research projects ... by Lyme Research Alliance, the nation's largest private nonprofit funder ... studies focus on the epidemiology of, and treatment and ... “LRA is proud to support the innovative research being ... men and women in the field today,” said Harriet ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
Breaking Medicine News(10 mins):Health News:Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3
... For immediate release -- Sept. 22, 2011 (Toronto) -- A ... recommends a public health approach to cannabis - including evidence-based ... that result from the use of cannabis. Led ... (Simon Fraser University, Vancouver) Dr. Benedikt Fischer, the study is ...
... class of medicines commonly given for pain -- were associated ... 3,061 adults, aged 65 to 94, e-published in advance of ... . The study from researchers at Group Health Research Institute ... which are drugs generally given for insomnia and anxiety, did ...
... 22 (HealthDay News) -- There were 134 waterborne disease ... in the United States in 2007-08, and 36 outbreaks ... released Thursday. The 134 recreational water illness outbreaks ... in 38 states and Puerto Rico, caused at least ...
... , THURSDAY, Sept. 22 (HealthDay News) -- Almost 7 percent of ... hospitalized within 30 days of the procedure, a new study indicates. ... who do not get prostate biopsies can expect to be hospitalized, ... Journal of Urology . "The overall hospitalization rate is about ...
... , THURSDAY, Sept. 22 (HealthDay News) -- Over-the-counter asthma ... layer, will not be made or sold after Dec. ... The sole product affected is Primatene Mist, marketed ... inhaler approved by the FDA to be sold without ...
... - The University of Kentucky,s Dr. Susanne Arnold and colleagues ... study potential environmental reasons for the high lung cancer rates ... three years and the study began on Sept. 15. ... but counties in the southeastern portion of the state ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
... multichannel pipettes speed up ... into microplates, with super ... volumes. The improved ergonomic ... multichannels, combined with super ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
Medicine Products: